Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

11,043 total articles

XDEMVY Is Carrying Tarsus — Pay Up, But Don’t Pay Blindly

XDEMVY Is Carrying Tarsus — Pay Up, But Don’t Pay Blindly

Tarsus has turned its FDA approval into real revenue: XDEMVY generated strong top-line growth and margin leverage in early 2026. The stock is not cheap on traditional multiples, but guidance for $670-700M in XDEMVY sales for 2026 narrows the gap between price and prospective value. This trade idea buys the story on continued execution while protect…

Buy the Rumor, Trade the Noise - A Tactical Long on Lionsgate

Buy the Rumor, Trade the Noise - A Tactical Long on Lionsgate

Lionsgate is once again in the headlines after M&A speculation and public denials created a volatility window. This is a tactical, event-driven long: enter at $6.50, stop at $4.75, with a primary target of $10.00 on a mid-term timeline (45 trading days). The trade bets that continued deal flow or asset-sale chatter will re-rate the stock before the…

Buy the Panic: Why Accenture's Plunge Looks Like an Overreaction

Buy the Panic: Why Accenture's Plunge Looks Like an Overreaction

Accenture (ACN) dropped into the low $120s after softer-than-expected revenue guidance and a heavy M&A cadence. Fundamentals - free cash flow, low net leverage, and a double-digit yield on cash flow - argue the sell-off is a stretched reaction. This trade idea outlines a long entry at $128.29, a conservative stop at $105, and a $220 target over 180…

Spero's Utebzi Approval: Why Yesterday's Dump Feels Like an Overreaction

Spero's Utebzi Approval: Why Yesterday's Dump Feels Like an Overreaction

Spero Therapeutics (SPRO) fell sharply after the FDA approval announcement for Utebzi (tebipenem pivoxil HBr) on 06/17/2026. The approval is a clear commercial milestone: the first oral carbapenem for complicated UTIs. With a market cap of roughly $132M, an enterprise value of ~$66M, and reported EPS near $0.26, the selloff looks disconnected from …

SCHD: A Defensive Dividend Shelter If AI Stocks Crack

SCHD: A Defensive Dividend Shelter If AI Stocks Crack

SCHD offers a 3.2% yield, low fees and a high-quality, dividend-weighted roster that historically holds up better than growth-heavy indexes in corrections. This trade idea lays out a clear long entry at $31.84, a stop at $30.25 and a first target at $32.80 for a mid-term hedge against an AI-sector sell-off.

EverCommerce: Buying a Vertical SaaS Growth Story at a Peer Discount

EverCommerce: Buying a Vertical SaaS Growth Story at a Peer Discount

EverCommerce (EVCM) is a vertically-focused SaaS roll-up serving service SMBs. The stock trades near $8.60 with a market cap roughly $1.52B and trading multiples that look conservative given improving free cash flow and recent AI / payments integrations. We lay out a long trade with entry, stop, and target for a 180-trading-day horizon and discuss …

Progressive Is Evolving Its Edge - Time to Buy PGR for a Re-Rate

Progressive Is Evolving Its Edge - Time to Buy PGR for a Re-Rate

Progressive has been quietly reshaping its business mix - growing personal auto premiums, squeezing underwriting margins above peers, and converting that advantage into free cash flow. The market has punished recent margin softness, pushing the stock to a valuation that looks attractive given $16.4B in trailing free cash flow and a P/E near 10. I a…

Micron: The AI Memory Squeeze Is Now — Time a Controlled Long

Micron: The AI Memory Squeeze Is Now — Time a Controlled Long

Micron is trading near fresh 52-week highs after a rupture in DRAM/NAND supply caused by AI data-center demand. Fundamentals show record revenue and very strong free cash flow, but the stock now sits at lofty multiples and faces cyclic risks. This trade proposes a mid-term long entry on a measured pullback, with a clear stop and a realistic target …

JD.com: Buy on Weakness for a 6-Month Rebound

JD.com: Buy on Weakness for a 6-Month Rebound

JD.com is trading like a cyclical e-commerce laggard but still offers a 3.5% dividend yield, a PB of ~1.4, and a market cap under $40B. Technicals show short-term oversold conditions and elevated short interest, creating a setup to buy on weakness with defined risk. This trade idea lays out entry, stop, targets, catalysts, and the key risks that co…